Clinical validity of brain fluorodeoxyglucose positron emission tomography as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework

Published 2017 View Full Article

Authors

Keywords

FDG PET, Biomarkers development, Early diagnosis, Biomarker-based diagnosis, Alzheimer's disease, 5-Phases

Journal

NEUROBIOLOGY OF AGING

Volume 52, Issue -, Pages 183-195

Publisher

Elsevier BV

Online

2017-03-17

DOI

10.1016/j.neurobiolaging.2016.03.033

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Become a Peeref-certified reviewer

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started